HLA-E-restricted immune response in EBV infection, the role of NRX-0492 in CLL, and NSAIDs for bone marrow failure in Ghosal Hematodiaphyseal Dysplasia
Blood Podcast
00:00
NRX0492 Degrades BTK in CLL Patients
NRX0492 inhibits BCR-mediated signaling, transcriptional programs, and chemokine secretion. In vitro experiment against treatment-nieve CLL samples revealed that the ability of NRX0492 to inhibit BCR was comparable to ibruetinib. Two clinical studies testing this approach are ongoing.
Transcript
Play full episode
